Chong Kun Dang announced on the 4th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase I clinical trial of CKD-508, its new drug candidate for dyslipidemia.

In the trial, Chong Kun Dang will confirm the safety and lipid-improving effects of CKD-508 and explore the optimal dose for a Phase II trial.

CKD-508 is a treatment for dyslipidemia that works by inhibiting the activity of cholesteryl ester transfer protein (CETP), which facilitates the transport of cholesteryl esters (CE) and triglycerides (TG) between lipoproteins in the blood, thereby lowering low-density cholesterol (LDL-C) levels and increasing high-density cholesterol (HDL-C) levels.

Son, Hyung Min(shm@dailypharm.com)